JP2020519672A - ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用 - Google Patents

ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用 Download PDF

Info

Publication number
JP2020519672A
JP2020519672A JP2019563217A JP2019563217A JP2020519672A JP 2020519672 A JP2020519672 A JP 2020519672A JP 2019563217 A JP2019563217 A JP 2019563217A JP 2019563217 A JP2019563217 A JP 2019563217A JP 2020519672 A JP2020519672 A JP 2020519672A
Authority
JP
Japan
Prior art keywords
cancer
ret
inhibitor
compound
mtorc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019563217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519672A5 (enExample
Inventor
エリカ エヴァンス ラーブ，
エリカ エヴァンス ラーブ，
ラミ ラハル，
ラミ ラハル，
Original Assignee
ブループリント メディシンズ コーポレイション
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブループリント メディシンズ コーポレイション, ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2020519672A publication Critical patent/JP2020519672A/ja
Publication of JP2020519672A5 publication Critical patent/JP2020519672A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2019563217A 2017-05-15 2018-05-15 ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用 Withdrawn JP2020519672A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762506334P 2017-05-15 2017-05-15
US62/506,334 2017-05-15
US201862652284P 2018-04-03 2018-04-03
US62/652,284 2018-04-03
US201862656297P 2018-04-11 2018-04-11
US62/656,297 2018-04-11
US201862657605P 2018-04-13 2018-04-13
US62/657,605 2018-04-13
PCT/US2018/032794 WO2018213329A1 (en) 2017-05-15 2018-05-15 Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity

Publications (2)

Publication Number Publication Date
JP2020519672A true JP2020519672A (ja) 2020-07-02
JP2020519672A5 JP2020519672A5 (enExample) 2021-07-26

Family

ID=62567777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563217A Withdrawn JP2020519672A (ja) 2017-05-15 2018-05-15 ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用

Country Status (5)

Country Link
US (1) US20210290620A1 (enExample)
EP (1) EP3624802A1 (enExample)
JP (1) JP2020519672A (enExample)
CN (1) CN110891573A (enExample)
WO (1) WO2018213329A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
EA038890B1 (ru) 2015-11-02 2021-11-03 Блюпринт Медсинс Корпорейшн Ингибиторы ret
CA3096043A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
JP2023501757A (ja) * 2020-05-29 2023-01-18 ブループリント メディシンズ コーポレイション プラルセチニブ薬学的組成物
KR20230017234A (ko) 2020-05-29 2023-02-03 블루프린트 메디신즈 코포레이션 프랄세티닙의 고체 형태
CN116867492A (zh) * 2020-11-20 2023-10-10 赫尔森保健股份公司 使用4-氨基-n-[4-(甲氧基甲基)苯基]-7-(1-甲基环丙基)-6-(3-吗啉代丙-1-炔-1-基)-7h-吡咯并[2,3-d]嘧啶-5-羧酰胺治疗肿瘤的方法
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079140A1 (en) * 2015-11-02 2017-05-11 Blueprint Medicines Corporation Inhibitors of ret

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047777A1 (en) 2005-05-26 2010-02-25 The Johns Hopkins University Methods for identifying mutations in coding and non-coding dna
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
EP2740742B1 (en) 2011-08-04 2018-03-14 National Cancer Center Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
AU2013259267A1 (en) * 2012-05-10 2014-11-06 Synta Pharmaceuticals Corp. Treating cancer with Hsp90 inhibitory compounds
JPWO2014017491A1 (ja) 2012-07-26 2016-07-11 国立研究開発法人国立がん研究センター Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子
SG11201502211QA (en) 2012-09-25 2015-05-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
PE20151538A1 (es) 2013-03-15 2015-11-18 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
US20150057335A1 (en) 2013-08-20 2015-02-26 National Cancer Center Novel fusion genes identified in lung cancer
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US9879021B2 (en) 2014-09-10 2018-01-30 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
PL3191450T3 (pl) 2014-09-10 2019-08-30 Glaxosmithkline Intellectual Property Development Limited Pochodne pirydonu jako inhibitory kinazy rearanżowanej podczas transfekcji (ret)
CA2967125C (en) 2014-11-14 2022-10-25 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079140A1 (en) * 2015-11-02 2017-05-11 Blueprint Medicines Corporation Inhibitors of ret

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. 23, no. 8, JPN6022006349, 2017, pages 1988 - 1997, ISSN: 0004708275 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol. 34, Issue 15 suppl., JPN6022006348, 2016, pages 9069, ISSN: 0004708274 *
LUNG CANCER, vol. 89, JPN6022006347, 2015, pages 76 - 79, ISSN: 0004708273 *

Also Published As

Publication number Publication date
EP3624802A1 (en) 2020-03-25
WO2018213329A1 (en) 2018-11-22
US20210290620A1 (en) 2021-09-23
CN110891573A (zh) 2020-03-17

Similar Documents

Publication Publication Date Title
JP2020519672A (ja) ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用
JP7019422B2 (ja) 癌を治療するための方法
US11872192B2 (en) RET inhibitor for use in treating cancer having a RET alteration
EP3585389A1 (en) Treatment of egfr-driven cancer with fewer side effects
CA2817564A1 (en) Preselection of subjects for therapeutic treatment based on hypoxic status
JP2021098750A (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2018531273A6 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2024528705A (ja) がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法
JP2022533100A (ja) Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
WO2020128620A1 (en) Use of il-1beta binding antibodies
TW202432142A (zh) 治療癌症之組合療法
RU2800951C2 (ru) Ингибитор ret для применения в лечении рака, имеющего ret-альтерацию
HK40046992A (en) Ret inhibitor for use in treating cancer having a ret alteration
HK40046992B (en) Ret inhibitor for use in treating cancer having a ret alteration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220817